VEGFA and age-related macular degeneration: Recent clinical trials have provided evidence that VEGF-trap administered every other month in patients with AMD can be as effective as monthly ranibizumab (Stewart et al, 2012a); likely due to its longer predicted intravitreal half-life (4.8 days versus 3.2 days; Stewart et al, 2012b) and its higher VEGF-binding affinity (Papadopoulos et al, 2012).